Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

abstract：INTRODUCTION:Neglected tropical diseases (NTDs) affect more than one billion people, mainly living in developing countries. For most of these NTDs, treatment is suboptimal. To optimize treatment regimens, clinical pharmacokinetic studies are required where they have not been previously conducted to enable the use of ph...

journal_title：Clinical pharmacokinetics

authors： Verrest L,Dorlo TPC

更新日期：2017-06-01 00:00:00

abstract：:A substantial proportion of migraine patients have gastric stasis and suffer severe nausea and/or vomiting during their migraine attack. This may lead to erratic absorption from the gastrointestinal tract and make oral treatment unsatisfactory. For such patients, an intranasal formulation may be advantageous. Sumatrip...

journal_title：Clinical pharmacokinetics

authors： Fuseau E,Petricoul O,Moore KH,Barrow A,Ibbotson T

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and ...

journal_title：Clinical pharmacokinetics

authors： Phelan M,Anzures-Cabrera J,Carlile DJ,Rowell L,Kuhlmann O,Arold G,Robson R,Bentley D

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free or total IAsp, and the relationship between anti-IAsp antibodies and the pharmacokinetics/pharmacody...

journal_title：Clinical pharmacokinetics

authors： Haahr H,Pieber TR,Mathieu C,Gondolf T,Shiramoto M,Erichsen L,Heise T

更新日期：2019-05-01 00:00:00

abstract：:The steady-state plasma concentrations of antipsychotic drugs show large interpatient variations but remain relatively stable from day to day in each individual patient. Monitoring of antipsychotic drug concentrations in plasma might be of value provided the patients are treated with only 1 antipsychotic drug. Some st...

journal_title：Clinical pharmacokinetics

authors： Dahl SG

更新日期：1986-01-01 00:00:00

abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

journal_title：Clinical pharmacokinetics

authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase o...

journal_title：Clinical pharmacokinetics

authors： Gras-Colomer E,Martínez-Gómez MA,Moya-Gil A,Fernandez-Zarzoso M,Merino-Sanjuan M,Climente-Martí M

更新日期：2016-09-01 00:00:00

abstract：:It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 micrograms/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of > or = 400 micrograms/L in the individ...

journal_title：Clinical pharmacokinetics

authors： Olesen OV

更新日期：1998-06-01 00:00:00

abstract：BACKGROUND:Because of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, e...

journal_title：Clinical pharmacokinetics

authors： Schlender JF,Meyer M,Thelen K,Krauss M,Willmann S,Eissing T,Jaehde U

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. METHODS:A populati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Li H,Zhu L,Bifano M,Eley T,Osawa M,Ueno T,Hughes E,Bertz R,Garimella T,AbuTarif M

更新日期：2017-10-01 00:00:00

abstract：:The critically ill patient occupies an increasing amount of time and bed space in modern hospital practice, and also commands increasing expenditure. Drug therapy in these patients has, in the past, been based on data derived from healthy volunteers, fit anaesthetised patients undergoing minor operative procedures, or...

journal_title：Clinical pharmacokinetics

authors： Bodenham A,Shelly MP,Park GR

更新日期：1988-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequen...

journal_title：Clinical pharmacokinetics

authors： González-Sales M,Barrière O,Tremblay PO,Nekka F,Mamputu JC,Boudreault S,Tanguay M

更新日期：2015-03-01 00:00:00

abstract：OBJECTIVE:Zanamivir, a clinically proven potent and specific inhibitor of influenza A and B neuraminidase, has been approved in some countries for the treatment of influenza and is in late-stage development for the prophylaxis of influenza. This study investigated whether the coadministration of zanamivir and influenza...

journal_title：Clinical pharmacokinetics

authors： Webster A,Boyce M,Edmundson S,Miller I

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:Reducing the dose of efavirenz can improve safety, reduce costs, and increase access for patients with HIV infection. According to the World Health Organization, a similar dosing strategy for all patient populations is desirable for universal roll-out; however, it remains unknown whether the 400 mg daily dos...

journal_title：Clinical pharmacokinetics

authors： Schalkwijk S,Ter Heine R,Colbers AC,Huitema ADR,Denti P,Dooley KE,Capparelli E,Best BM,Cressey TR,Greupink R,Russel FGM,Mirochnick M,Burger DM

更新日期：2018-11-01 00:00:00

abstract：OBJECTIVE:To study the pharmacokinetics of micafungin in intensive care patients and assess pharmacokinetic (PK) target attainment for various dosing strategies. METHODS:Micafungin PK data from 20 intensive care unit patients were available. A population-PK model was developed. Various dosing regimens were simulated: ...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Ter Heine R,Schouten JA,Hunfeld NG,van Leeuwen HJ,Verweij PE,de Lange DW,Pickkers P,Brüggemann RJ

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. This work characterized upadacitinib population pharmacokinetics in healthy subjects and RA patients and the effects of covariates on upadacitinib ex...

journal_title：Clinical pharmacokinetics

authors： Klünder B,Mohamed MF,Othman AA

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. OBJECTIVE:The purpose of our study was to investigate the pharmacokinetics (PK) of pemet...

journal_title：Clinical pharmacokinetics

authors： de Rouw N,Boosman RJ,Huitema ADR,Hilbrands LB,Svensson EM,Derijks HJ,van den Heuvel MM,Burger DM,Ter Heine R

更新日期：2021-01-09 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. The aim of this phase II, crossover, bioequivalence study was to compare the pharmacokinetics (primary objective) and tolerability (secondary objective) of tegafur-uracil (UFT) given as three daily doses (tid, r...

journal_title：Clinical pharmacokinetics

authors： Etienne-Grimaldi MC,François E,Cardot JM,Renée N,Douillard JY,Gamelin E,Bennouna J,Château Y,Milano G

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bosentan is a competitive antagonist on endothelin receptor A and B (ETA and ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependen...

journal_title：Clinical pharmacokinetics

authors： Volz AK,Krause A,Haefeli WE,Dingemanse J,Lehr T

更新日期：2017-12-01 00:00:00

abstract：:The pharmacokinetics of gentamicin were studied after total hip joint arthroplasties in 2 groups of 10 patients. The prosthesis was performed in the first group with 'Palacos R plus gentamicin' (normal viscosity), manufactured by Schering, and in the second group with 'Cerafix genta R' (low viscosity) manufactured by ...

journal_title：Clinical pharmacokinetics

authors： Bunetel L,Segui A,Cormier M,Langlais F

更新日期：1990-10-01 00:00:00

abstract：:Carbamazepine is one of the most commonly prescribed antiepileptic drugs and is also used in the treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar depression. Because of its widespread and long term use, carbamazepine is frequently prescribed in combination with other drugs, leading to ...

journal_title：Clinical pharmacokinetics

authors： Spina E,Pisani F,Perucca E

更新日期：1996-09-01 00:00:00

abstract：:There are considerable laboratory data and information from animal and continuous culture in vitro models to support continuous infusion therapy for penicillins and cephalosporins, but, as yet, the only existing clinical data relate to cephalosporins. Penicillins do not exert concentration-dependent killing in the the...

journal_title：Clinical pharmacokinetics

authors： MacGowan AP,Bowker KE

更新日期：1998-11-01 00:00:00

abstract：:Therapeutic drug monitoring is now widely used in many areas of medicine. With its proliferation has come an understanding of the clinical situations in which it is likely to be of value. Factors that can limit the usefulness of therapeutic drug monitoring and situations where it is less likely to be of benefit have a...

journal_title：Clinical pharmacokinetics

authors： Moore MJ,Erlichman C

更新日期：1987-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Elagolix is an oral, non-peptide, gonadotropin-releasing hormone receptor antagonist. It is approved for the treatment of moderate-to-severe pain associated with endometriosis and is being investigated for the treatment of heavy menstrual bleeding associated with uterine fibroids. Use of low-do...

journal_title：Clinical pharmacokinetics

authors： Nader A,Mostafa NM,Ali F,Shebley M

更新日期：2021-01-01 00:00:00

abstract：:Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR signaling pathway, i...

journal_title：Clinical pharmacokinetics

authors： Long A,Chigutsa E,Wallin J

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better understanding of the influence of ethnicity on drug response to minimize duplication of clinical studies, thereby expediting drug approval. OBJ...

journal_title：Clinical pharmacokinetics

authors： Barter ZE,Tucker GT,Rowland-Yeo K

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Iron-rich transfusions and/or a compensatory increase in iron absorption ultimately result in iron loading in patients with β-thalassaemia. Hence, without iron chelation, iron accumulates relentlessly. Deferiprone has been shown to be capable of reducing the iron burden in patients with β-thala...

journal_title：Clinical pharmacokinetics

authors： Limenta LM,Jirasomprasert T,Jittangprasert P,Wilairat P,Yamanont P,Chantharaksri U,Fucharoen S,Morales NP

更新日期：2011-01-01 00:00:00

abstract：:Antibiotic therapy is one of the main treatments for cystic fibrosis (CF). It aims to eradicate bacteria during early infection, calms down the inflammatory process, and leads to symptom resolution of pulmonary exacerbations. CF can modify both the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of antibiotics,...

journal_title：Clinical pharmacokinetics

authors： Magréault S,Roy C,Launay M,Sermet-Gaudelus I,Jullien V

更新日期：2021-01-24 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclizumab high-yield process (DAC HYP) is a humanized monoclonal antibody that selectively blocks the α-subunit (CD25) of the high-affinity interleukin-2 receptors, and has shown robust efficacy as a treatment for multiple sclerosis (MS). This work quantitatively characterized the relationship...

journal_title：Clinical pharmacokinetics

authors： Minocha M,Tran JQ,Sheridan JP,Othman AA

更新日期：2016-01-01 00:00:00

abstract：:Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is...

journal_title：Clinical pharmacokinetics

authors： Fahr A

更新日期：1993-06-01 00:00:00